# Simplify Genomics

The Tech-Enabled Platform Turning Genomic Data into Actionable Healthcare Solutions

- Canonical URL: https://wefunder.com/simplify.genomics
- Entity ID: wefunder:company:155980
- Last updated: 2026-06-07T05:03:09Z
- Generated at: 2026-06-07T06:26:34Z

## Quick facts
- Tracking to $1.5M to $2M in ARR in 2024
- Technology validated over 7+ years with 9 updated versions and 10k+ clinical reports issued
- CEO previously built and sold a successful genomics tech platform
- Spin out of genomic company founded by Craig Venter who sequenced the first human genome
- De-risked investment with $90M prior development funding, clean cap table, and virtually no debt
- Scalable, automated platform; able to profitably offer whole genome clinical report under $1,000
- Our search engine rapidly analyzes data at 'speed of thought,' unlocking Google-like monetization

## Active fundraises
- wefunder:fundraise:115326: 4(a)(6) successful (USD)
- wefunder:fundraise:115325: 4(a)(6) successful (USD)

## Story
More than 20 years after the first human genome was sequenced, genomics is stalled in a data flood. Human genomes are sequenced quickly and inexpensively, yet clinicians are left reviewing the first page of a highly limited report, leaving powerful data buried and unusable.Demand for whole genome sequencing is rising rapidly as sequencing costs decline. The challenge has shifted from a sequencing problem to a data problem as the industry struggles to make clinical sense of all the genomic information (6.4B pieces of data from one human genome!). Currently, the interpretation of the data is done by bioinformaticians and genomic scientists making subjective decisions on a tiny subset of data, and this reliance on people to make decisions is driving costs back up.As an industry, we are on the precipice of discovery that will enable the identification, creation, and commercialization of vastly improved patient treatments. By tapping into the full power of the genome, clinicians can quickly assess genomic similarities between patients, providing the right treatment to the right patient and limiting side effects. We believe this will revolutionize healthcare!We believe Simplify Genomics has created the next-generation platform to realize these discoveries and finally make use of the data flood. Solving the Data Problem with Smart GenomeOver the last 7 years, Simplify Genomics has built Smart Genome, an automated genome reporting platform designed for scale to empower genomics in healthcare. Simply put, it makes practical clinical use of deep genomic data, finally bringing healthcare into the future.Since 2018, our platform has curated over 7,000 genes and millions of variants, producing over 10,000 clinically actionable whole genome reports. AI-driven and validated, our platform supports seamless content expansion, with nine versions released over seven years.Smart Genome was developed by an expert team under Craig Venter – the first person to sequence the human genome – and leveraged decades of insight to create our platform. Our Technology StackSimplify Genomics’ technology is a three-tiered suite to empower the future of genomics in healthcare.1. Simplify Genome: Clinical whole genome reporting CLIA-certified and CAP-accredited dry laboratory that delivers actionable insights from whole genome sequencing. Our content is AI-informed and explainable, ensuring scalable, fast, and reproducible clinical reporting.2. Simplify Search: Fast, accurate, insightful genome explorationAn AI technology platform that quickly provides access to raw genetic data, clinical information, and the latest insights in genomics. Similar to Google, users can access information through a user-friendly interface that queries hundreds of millions of genomic variants at the speed of thought.3. Simplify Data: Multi-source, rich data repository An aggregation of public, proprietary, and clinical data that empowers discovery and research, serving as the foundation of the Genome and Search platforms.For a more technical look at our Search platform, see the following video:With our groundbreaking solutions, we can finally interpret genomic data quickly enough and at the scale needed for clinical actionability. With the right data, we can match genetically similar patients to predictable outcomes, putting powerful science behind personalized healthcare. This technology moves us toward personalized medicine and can extend lifespans.Furthermore, our platform uses AI to quickly generate deeper reports, eliminating the need for costly manual work while significantly reducing time and expenses.Proven Company Simplify Genomics started in 2016 under our former parent company, Human Longevity. Founded in 2013 by Craig Venter, the person credited with sequencing the first human genome, Human Longevity focused on developing solutions around the whole genome, with over $400 million in investment into the parent company. In 2022, Simplify Genomics spun out of Human Longevity, leveraging years of expertise and $90 million of development to create our platform. Today, Human Longevity exclusively uses Simplify Genomics reports to guide clinical decisions for its Longevity Program. Simplify has accomplished the following: Built an automated AI system to produce clinical reports from raw genomic data seamlessly.Created a market-leading comprehensive genomic screening report that covers multiple diseases.Developed breakthrough search technology for instant analysis of genomic and clinical data.Assembled a database with over 35k whole genomes and 400 million unique variants – expected to surpass 100,000 whole genomes and more than 1 billion distinct variants in the next six months!Compiled a curated database of 1.6 million genetic variants, linking each to diseases and assessing their risk level.We have demonstrated initial market acceptance and revenue generation, generating between $1.5M and $2M of revenue annually, primarily from Human Longevity.(Forward-looking projections not guaranteed)Market Demanding ChangeAs sequencing prices rapidly decline after years of stagnation, the healthcare industry is moving to whole genome sequencing as a backbone, creating optimal timing for Simplify. Our initial target market is the large and growing concierge medicine and executive health market, which will use our reports as an addition to their current offerings. This market is eager for new content to differentiate itself and better treat its patients and our screening reports give them that edge. We are at the forefront of this transition.We believe this target market will allow Simplify to achieve positive cash flow in under 12 months and then expand into additional markets. Please note that future projections aren't guaranteed. Profitable Business ModelSimplify is a rare opportunity in the healthcare technology sector. Our profitability may be extremely close on the front end, and our valuation growth may be exponential on the back end. This is possible due to the $90M+ development funding prior to the spin-out and our team's deep experience.  As Simplify’s solution is adopted, there are additional monetization streams, including significant recurring revenue opportunities through a subscription model. (Forward-looking projections not guaranteed)Leading the CompetitionSimplify Genomics is entering a market poised for disruption. Current products have limited clinical utility. Our Smart Genome platform paves the way for something entirely new by equipping clinicians to fully leverage raw genomic data, positioning us to be a leader in an industry primed for major change.Our report is much broader, more clinically actionable, and lower in cost. Additionally, our search engine provides groundbreaking access to information that revolutionizes patient care by utilizing raw data beyond the clinical report at the speed of thought.Future OpportunitiesAs a lean company, we are hyper-focused on the short-term plan and commercializing our market-leading report. That being said, our full platform suite has significant future upside opportunities that can dramatically increase the business's enterprise value.Simplify can address multiple commercial avenues, such as an end-to-end reporting solution, large-scale Simplify Search adoption, and subscription models.There is ample industry precedent for acquisition in the healthcare technology sector - a likely outcome for Simplify Genomics in the foreseeable future.Precedent AcquisitionsPierian was acquired by VelseraEmedgene was acquired by IlluminaNof1 was acquired by QiagenDeepLens was acquired by ParadigmTrapelo Health was acquired by NeoGenomicsTeam of Industry ExpertsSimplify’s team consists of industry veterans with experience building and selling a health tech platform. Previously, working together at Human Longevity under industry pioneer Craig Venter, they developed the platform that is now Smart Genome, giving them deep expertise in its code and architecture.Our co-founder and CEO, Travis Lacey, has a background in business, including as an investment banker. Lacey built a successful oncology platform that sequenced high-quality data from tumor tissue and interpreted it into clinically relevant information for drug development. In 2020, it was acquired by NeoGenomics Laboratories, significantly exceeding investor expectations.We have successfully leveraged the strength of our lean but passionate team to get Simplify to its current state. The Use of FundsToday, Simplify Genomics is raising $5 million to expand commercially and continue the product development of Smart Genome.The investment thesis has been de-risked, given that Simplify has a clear market problem, a proven solution, a validated technology platform, CLIA certification and CAP accreditation, and initial market acceptance. In addition, we have $90M in prior development funding, and a clean cap table, making this opportunity a high-potential investment. As genomics takes center stage in clinical, biotech and pharma markets, Simplify Genomics is strategically positioned to lead the future of personalized medicine. Join us in transforming genomic data to dramatically improve patient outcomes at the speed of thought!

## FAQ
1. **Hi, Very interesting. Can you please tell us about your IP portfolio? Thanks. Blessings**
   - Thank you for your question. We have exclusive worldwide rights to the patents that we need for Simplify and the right to prosecute those patents. Please don't hesitate to let me know if you have more questions. Thank you for your consideration.
2. **Dear Sirs, I am Giovanni Diamante and I have tried to file an investment in Simplified Genomics, but I cannot close it to send it to you. What I am missing? Regards, Giovanni gfdiamante@yahoo.com**
   - Giovanni - are you still having issues? I can talk to Wefunder about having someone follow-up with you. Thank you.
3. **Hello Travis, Greetings! Love your initiative. I am an Angel investor. Have few questions - Is there a liquidation preference or preference overhang in the cap table? - Given the uniqueness of the platform, wonder why Human Longevity is your only customer? Where do you see the...**
   - No overhang or liquidation preference in the cap table - standard common and preferred. On the Human Longevity question, we are now bringing on new customers but it has all been through word of mouth. Part of use of funds will be to expand commercially - we are also launching in 1Q w a large imaging center combining our WG report with their WB MRI (cash pay). The revenue decline was all due to us continuing to bring our prices down to a point where we can drive more volume. At the same time, ...
4. **I am an obstetrician/gynecologist and a functional medicine practitioner since 2005. I did my first microarray for methylation pathway with Dr Amy Yasko in 2005 and HLA gene typing in 2010 and have been practicing nutrigenomics since then with great relief of some symptoms, so...**
   - Hi Bina, thanks for your interest and questions. We are excited about where we can take this company and our approach to scientifically-based preventative care. HLA-typing and methylation are areas of interest to us, but we must stay focused in the short term. I would like to address your specific questions. 1. For clinical genome interpretation, we rely on scientific findings from published studies, public and licensed genomic data sources, and our internal proprietary data. This allows us t...
5. **I assume your company has patents regarding your technology. If so, I would add a section about that on Wefunder unless I missed it as I read through. If you do, roughly what does it cover/how do they set your company apart from any competitors?**
   - Thank you for your question and suggestion. Yes we have been given exclusive worldwide license on the patents around our Search engine that allow users to search raw genomic and clinical information in a quick and efficient manner. The ability to upload thousands of whole genomes, get that information organized, and enable non-technical users to search that information in “google speed” is a huge differentiator from what is available on the market today. I would be happy to discuss further an...

## Team
- Travis Lacey (Co-Founder and CEO)
- Wayne Delport (Co-Founder and Chief Technology Officer)

## Recent posts
- Simplify Genomics / TMA Precision Health (2025-08-04T22:07:13Z)
- Simplify Genomics | Investor Update – 1H 2025 (2025-07-29T19:54:51Z)
- Partnership Update (2025-02-18T21:00:25Z)
- My "Why" - The Story of My Father (2024-11-15T02:24:38Z)

## Q&A
- Q: Is there a way to get tested myself so I can see what is the output from testing and better understand how individuals or their doctors might use the data from your testing.
  - A: Colin - apologies for the delayed response. We have not set up a DTC option yet as we have to work through a clinician but we will be working on an offering in the future to allow consumers to order through a physician network as we expand.
- Q: Hi, Very interesting. Can you please tell us about your IP portfolio? Thanks. Blessings
  - A: Thank you for your question. We have exclusive worldwide rights to the patents that we need for Simplify and the right to prosecute those patents. Please don't hesitate to let me know if you have more questions. Thank you for your consideration.
- Q: Who has invested
- Q: What is your month burn rate? It looks low but Kingscrowd has it listed at 1.5 million a month.
  - A: Our burn rate is approximately 50k - 60k per month. We have continued to lower that rate (through optimizing our costs and revenue/margin increases) since we spun out and project getting to CF+ in '25.
- Q: I am a clinical lab scientist in molecular in one of the biggest independent labs in the Midwest. Genetics and precision medicine is a growing industry that will have so much opportunity in the future. With the FDA LDT regulations happening and future phase out of in lab testing that is not patented or FDA approved that are supposed to be in effect by 2027. It can be a loss of opportunity and potential revenue for the demand of software from smaller independent laboratories in the county. I am curious as to what the company can do to minimize potential loss of opportunities. How does the company plan to make more deals and more profit if fewer laboratories/ companies will be able to utilize the product? What kind of strategies will you the company implement to maximize growth?
  - A: Hi David, thank you for your interest and question. First and foremost, it is essential to understand that we are not a software-only company - we are a CAP-accredited and CLIA-certified laboratory that has developed software tools to enhance our internal operations. Our customers are not laboratories but health systems, clinicians, and physicians who want to use our services to improve patient care. As a result, we are currently an LDT regulated by CAP and CLIA. As you point out, the regulation landscape is changing, and we are keeping up with these developments. With the FDA's intent to regulate LDTs, we would have to prepare a 510k or pre-market submission, although there are other options - such as NY state approval, that at this stage appears to be a waiver for a 510k. Furthermore, note that the change in regulation does not prevent us from being able to operate as a laboratory in the future; it only requires us to do additional work for regulatory purposes. We have planned for this in our raise and use of funds roadmap. It is still being determined how software-only systems will be regulated; we are also monitoring this. These regulation changes may help us open new opportunities for customers who have lost access to unregulated software systems and are looking for regulated end-to-end workflows.
- Q: Can you share your thoughts on how often you will update us on how things are progressing with your goals and business plan? Secondly, do you intend to file the annual report with the SEC? Thanks for your feedback.
  - A: Karolina - thank you for your question and interest in investing. Yes - I want to be transparent about how we communicate our progress and challenges, and what you can expect from us. Every quarter we will share an update about the business. These will be posted as a Wefunder Update and you'll get an email when they’re posted. Second, we do intent to file the annual report per the SEC. Thank you again for your consideration and if you have any additional questions, please feel free to follow back up.
- Q: hi
- Q: Can you explain why Human Longevity (HL) spun Simplify Genomics off? I'm a bit confused as to why HL would spin the company off HL was both the largest investor and only major customer. Can you please add some color and commentary to this? Thx.
  - A: Mike – Thank you for the question. My co-founder and I proposed to the Board at HLI back in late 2021 the concept of spinning off the genomic technology engine out of HLI. The reason they decided to move forward with our proposal was because Simplify as a separate company could solely focus on developing the technology and selling to additional customers as we knew that we had a solution and product that was applicable to a much broader audience than just HLI. Second, it allowed HLI to focus on being the pre-eminent longevity center in the world and delivering proactive and preventive care utilizing the world’s best technologies, including our clinical whole genome report. Last, as we continue to grow Simplify, Human Longevity maintains an ownership position and once we have a liquidity event, HLI would also participate through their equity ownership. Please let me know if you have additional questions and happy to discuss as well.
- Q: Hi Travis. This sounds like a terrific opportunity. Many managements I have backed do not provide any updates, some for years after the offering ends. Will you commit to keeping us updated on how our investment is doing?
  - A: Yes. We are sending out our communication strategy to the investors this week to set expectations on quarterly updates. You have entrusted us with a financial commitment and we do not take that lightly. You can also follow Simplify Genomics on LinkedIn and we will provide periodic updates there as well. Please let me know if you have additional questions and I would be happy to answer.
- Q: I am an obstetrician/gynecologist and a functional medicine practitioner since 2005. I did my first microarray for methylation pathway with Dr Amy Yasko in 2005 and HLA gene typing in 2010 and have been practicing nutrigenomics since then with great relief of some symptoms, so am very familiar with the science, and see value in your approach. I have invested in Predictiv care who is doing a whole genome, as a digital twin. I want to invest in simplify genomics. However, I have following questions : 1. You have clinical data of the phenotype on only 10000 patients, Is that enough to make reports on general population which runs in millions? I do understand one has to start somewhere and perhaps future experience will give more numbers and data to make reports more comprehensive. 2. Can you use previously done genome testing elsewhere to give clinically relevant report ? 3. Since we know our microbiome genetics affect us as well and have a tremendous part to play in disease occurence, how is that addressed in your report to prevent disease? Thanks. Bina C. Souri MD.FACOG.
  - A: Hi Bina, thanks for your interest and questions. We are excited about where we can take this company and our approach to scientifically-based preventative care. HLA-typing and methylation are areas of interest to us, but we must stay focused in the short term. I would like to address your specific questions. 1. For clinical genome interpretation, we rely on scientific findings from published studies, public and licensed genomic data sources, and our internal proprietary data. This allows us to benefit from the extensive body of scientific knowledge and our internal assessment and interpretation of genomic data. Our strength is making sense of the billions of genome interpretation records available through these sources. 2. We are a CAP-accredited and CLIA-certified laboratory. We require that a physician place an order for our report and that sequencing be conducted by a similarly CAP-accredited and CLIA-certified laboratory that we have verified for our testing purposes. Therefore, we can only accept raw data for clinical genome interpretation if it is from a laboratory that we have qualified as one of our reference laboratories. 3. We do not include microbiome interpretations in our report. Our team has some experience in microbiome analysis (from Human Longevity), but this is not currently a product we offer. I hope that answers your questions, but please don't hesitate to let us know if you have any more.
- Q: Thanks Travis for your response. I sent you a message on Linkedin, we shall take the discussion offline.
- Q: Hello Travis, Greetings! Love your initiative. I am an Angel investor. Have few questions - Is there a liquidation preference or preference overhang in the cap table? - Given the uniqueness of the platform, wonder why Human Longevity is your only customer? Where do you see the friction in adoption and customer acquisition? - I see a revenue decline in 2023 and your accounts payable went up significantly. Wanted to get your thoughts. - Who are your tier1/2 competitors? - You mentioned about addressing the market of executive health. Would be great if you could share pointers to any available material. - Does this investment qualify for QSBS1202 tax credit? Thanks in advance for responding to my questions. It will immensely help with my decision making process.
  - A: No overhang or liquidation preference in the cap table - standard common and preferred. On the Human Longevity question, we are now bringing on new customers but it has all been through word of mouth. Part of use of funds will be to expand commercially - we are also launching in 1Q w a large imaging center combining our WG report with their WB MRI (cash pay). The revenue decline was all due to us continuing to bring our prices down to a point where we can drive more volume. At the same time, we are driving our costs down at the same rate so we can remain cash flowing on a per report basis. Our vendors have been working with us and we are going to do partnerships with our two largest vendors so we can reduce our costs substantially. Our competitors that we will and have seen the most are companies like Invitae - they have a healthy genome report but it is extremely limited and the Company was just purchased by LabCorp. Send me your email address and I would be happy to set up time to discuss further. By the way, I am unsure on the QSBS credit but can check into that. I appreciate your consideration and look forward to speaking more.
- Q: I havent seen an update in a very long time. Are you still in business?
  - A: Richard - apologies for the delay in an update. If you have questions on the update, please let us know. We are going to be updating on a more frequent basis
- Q: Is there an update of how you are doing according to your plans?
  - A: Thanks Luis and we are going to post more frequent updates in the future. please let me know if you have any questions
- Q: Hello any financials for 1 Q 2025 ? Regards Richard Clement MD